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Background: Fatty acid-binding protein 4 (FABP4) is expressed in both adipocytes and macrophages. Recent studies
have shown secretion of FABP4 from adipocytes and association of elevated serum FABP4 level with obesity, insulin
resistance, hypertension, and atherosclerosis. However, little is known about role of FABP4 in cardiac function.
Methods: From the database of the Tanno-Sobetsu Study, data for 190 subjects (male/female: 82/108) who were not
treated with any medication and underwent echocardiography in 2011 or 2012 were retrieved for analyses of
relationships between serum FABP4 concentration, metabolic markers and parameters of echocardiography.
Results: Serum FABP4 level was positively correlated with age, body mass index (BMI), blood pressure (BP), LDL
cholesterol, HOMA-R and mean left ventricular (LV) wall thickness (LVWT, males: r = 0.315, females: r = 0.401,
p < 0.01) and was negatively correlated with HDL cholesterol, estimated glomerular filtration rate (eGFR) and
peak myocardial velocity during early diastole (e’; males: r = −0.434, females: r = −0.353, p < 0.01), an index of LV
diastolic function. However, no significant correlation was found between FABP4 level and LV end-diastolic
dimension, LV ejection fraction or LV mass index. There were significant correlations of e’ with age, BMI, BP,
eGFR, brain natriuretic peptide (BNP), FABP4, metabolic markers and LVWT. Multivariate regression analysis
adjusted by HOMA-R, BMI, eGFR, BNP or LVWT in addition to age, gender and BP revealed that serum FABP4
concentration was independently correlated with e’.
Conclusions: Elevation of circulating FABP4 may contribute to LV diastolic dysfunction in a general population.
Keywords: Fatty acid-binding protein 4, Adipokine, Left ventricular diastolic dysfunctionBackground
Fatty acid-binding proteins (FABPs) are a group of intra-
cellular lipid chaperones that coordinate lipid responses
in cells [1,2]. FABPs are about 14-15-kDa proteins that
can reversibly bind hydrophobic ligands, such as saturated
and unsaturated long chain fatty acids, with high affinity
[1,2]. FABPs have been proposed to facilitate the transport
of lipids to specific compartments in the cell. Among
FABPs, fatty acid-binding protein 4 (FABP4), known as* Correspondence: furuhasi@sapmed.ac.jp
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unless otherwise stated.adipocyte FABP (A-FABP) or aP2, is expressed in adipo-
cytes, macrophages and capillary endothelial cells [1-3].
Emerging evidence indicates that FABP4 acts at the inte-
gration between metabolic and inflammatory pathways
and plays an important role in the development of insulin
resistance and atherosclerosis [4-6]. It has also been
demonstrated in experimental models that chemical
inhibition of FABP4 could be a therapeutic strategy
against insulin resistance, diabetes mellitus, fatty liver
disease and atherosclerosis [7].
Adipose tissue is now known to secrete a variety of
bioactive molecules called adipokines, such as tumor
necrosis factor-α (TNFα), leptin and adiponectin, which
are implicated in a wide range of biological phenomena.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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secreted from adipocytes [8,9], though there are no typ-
ical signal peptides for secretion in the sequence of
FABP4 [1]. It has also been demonstrated that secretion
of FABP4 is via a non-classical secretion pathway and
that FABP4 acts as an adipokine for the development of
hepatic insulin resistance [9]. Furthermore, elevated
serum concentration of FABP4 has been shown to be
associated with obesity, insulin resistance, hypertension
and atherosclerosis [8-12].
Obesity is a risk factor for several kinds of cardiac
insults, such as left ventricular (LV) hypertrophy, LV
diastolic dysfunction and heart failure with preserved
or reduced ejection fraction. It has been suggested that
several adipokines provide a direct pathophysiological
link between enlarged adipose tissue and obesity-associated
cardiac dysfunction [13]. However, little is known
about the relationship between circulating FABP4 and
cardiac function, especially in a general population.
Therefore, we hypothesized that increase in serum
FABP4 reflects LV diastolic dysfunction as an early
stage of cardiac insults in a general population. To ad-
dress this hypothesis, we conducted a study to investi-
gate the cross-sectional associations between serum
FABP4 concentration and several echocardiographic




The Tanno-Sobetsu Study is a study with a population-
based cohort design recruiting residents of two rural
towns, Tanno and Sobetsu, in Hokkaido and includes
annual health examination, pathophysiological assess-
ment of metabolic syndrome and cardiovascular disease,
and follow-up survey. A total of 357 female subjects
(mean age: 66 ± 13 years) in 2011 and 277 male subjects
(mean age: 66 ± 13 years) in 2012 received annual exam-
inations in Sobetsu Town. Female and male participants
in 2011 and 2012, respectively, were invited to receive
echocardiographic examinations. Subjects who were
being treated with any regular medications for diseases
were excluded. Other exclusion criteria were atrial fib-
rillation and conductional abnormalities such as left
bundle branch block on electrocardiogram or severe
valvular disease and left ventricular hypertrophy (wall
thickness >12.5 mm) on echocardiogram. A total of 190
subjects who underwent echocardiography (male/female:
82/108, mean age: 63 ± 13 years) contributed to the present
analyses. This study conformed to the principles outlined
in the Declaration of Helsinki and was performed with the
approval of the Ethical Committee of Sapporo Medical
University. Written informed consent was received from
all of the subjects.Measurements
Medical check-ups were performed between 06:00 h and
09:00 h after an overnight fast. After measuring anthropo-
metric parameters, blood pressure was measured twice
consecutively on the upper arm using an automated sphyg-
momanometer (HEM-907, Omron Co., Kyoto, Japan) with
subjects in a seated resting position, and average blood
pressure was used for analysis. Body mass index (BMI)
was calculated as body weight (in kilograms) divided by
the square of body height (in meters). Peripheral venous
blood samples were obtained from study subjects after
physical examination for complete blood count and bio-
chemical analyses of the serum. The serum samples were
analyzed immediately or stored at −80°C until biochemical
analyses.
Serum concentration of FABP4 was measured using a
commercially available enzyme-linked immunosorbent
assay kit for FABP4 (Biovendor R&D, Modrice, Czech
Republic). The accuracy, precision and reproducibility of
the kit have been described previously [8]. The intra- and
inter-assay coefficient variances in the kit were < 5%. Fast-
ing plasma glucose was determined by the glucose oxidase
method. Fasting plasma insulin was measured by a radio-
immunoassay method (Insulin RIA bead, Dianabot, Tokyo,
Japan). Creatinine (Cr) and lipid profiles, including
total cholesterol, high-density lipoprotein (HDL) chol-
esterol and triglycerides, were determined by enzymatic
methods. Low-density lipoprotein (LDL) cholesterol level
was calculated by the Friedewald equation. Hemoglobin
A1c (HbA1c) was determined by a latex coagulation
method and was expressed in national glycohemoglobin
standardization program (NGSP) scale. Brain natriuretic
peptide (BNP) was measured using an assay kit (Shionogi &
Co., Osaka, Japan). High-sensitivity C-reactive protein
(hsCRP) was measured by a nephelometry method. As
an index of renal function, estimated glomerular filtration
rate (eGFR) was calculated by an equation for Japanese:
eGFR(ml/min/1.73m2) = 194 ×Cr(‐ 1.094) × age(‐ 0.287) × 0.739
(if female). HOMA-R, an indicator of insulin resistance,
was calculated by the previously reported formula: in-
sulin(μU/ml) × glucose(mg/dl)/405.
Echocardiography
After medical check-ups and collection of urine and blood
samples, echocardiographic examinations were performed
by three well-experienced echocardiographers who were
blinded to clinical data, using Vivid 9 (GE Health Care,
Tokyo, Japan) equipped with a 2.5-MHz frequency
transducer. Two-dimensional and color tissue Doppler
imaging modes were used to obtain images from standard
echocardiographic views, including parasternal long-axis
and apical four-, three-, and two chamber views at a
left lateral decubitus position. Standard parameters in
two-dimensional measurements, including LV end-diastolic
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wall thicknesses at end-diastole (mm), were determined.
Mean LV wall thickness (mm) was calculated by the aver-
age of septal and posterior wall thicknesses at end-diastole.
LV ejection fraction (%) was calculated using biplane modi-
fied Simpson’s method. LV mass was calculated according
to the recommendations of the American Society of
Echocardiography [14] and normalized for body surface
area (LV mass index, g/m2). Left atrial (LA) dimension
(mm) was measured by M-mode echocardiography, and
LA volume was measured using biplane Simpson’s method
and normalized for body surface area (LA volume index,
ml/m2) [14]. Each parameter was evaluated by averaging
two to three measurements. Transmitral flow velocities
were obtained by pulsed wave Doppler echocardiography,
positioning a sample volume at the level of a mitral tip in
an apical four-chamber view. Mitral flow parameters, in-
cluding peak velocities during early (E) and late diastole (A)
and E-wave deceleration time, were measured, and the E/A
ratio was calculated. Tissue velocity curves were obtained
from color tissue Doppler imaging. A sample volume was
placed at the lateral annulus in the apical four-chamber
view, and peak myocardial velocity during early diastole
(e’ , cm/sec) was measured, and the ratio of mitral to myo-
cardial early diastolic peak velocity (E/e’) was calculated.
Statistical analysis
Numeric variables are expressed as means ± SD for normal
distributions or medians (interquartile ranges) for skewed
variables. The distribution of each parameter was tested
for its normality using the Shapiro-Wilk W test, and
non-normally distributed parameters were logarithmic-
ally transformed for comparison and regression analyses.
Comparison between two groups was done with an
unpaired t test. One-way analysis of variance and
Tukey-Kramer post hoc test were used for detecting signifi-
cant differences in data between multiple groups. The
correlation between two variables was evaluated using
Pearson’s correlation coefficient. Multivariate regression
analysis was performed to identify independent determi-
nants of e’ using the variables with a significant and non-
confounding correlation in simple regression analysis as
independent predictors, showing the t-ratio calculated as
the ratio of regression coefficient and standard error of
regression coefficient and the percentage of variance in the
object variables that they explained (R2). A p value of less
than 0.05 was considered statistically significant. Holm-
Bonferroni sequential correction was also performed in
multivariate regression analysis. All data were analyzed by
using JMP 9 for Macintosh (SAS Institute, Cary, NC).
Results
Basal characteristics of the study subjects are shown in
Table 1. Male subjects were significantly older than thefemale subjects and they had significantly larger BMI and
waist circumference and had higher levels of systolic and
diastolic blood pressures, triglycerides, glucose, HbA1c,
insulin, HOMA-R and Cr and lower levels of total choles-
terol, HDL cholesterol, LDL cholesterol and FABP4 than
did the females. No significant difference in eGFR or BNP
was found between male and female subjects. In echocar-
diographic parameters, LA dimension, mean LV wall
thickness, LV end-diastolic dimension, LV mass index and
E-wave deceleration time were significantly larger in males
than in females. On the other hand, LV ejection fraction
and E/A ratio were smaller in males than in females.
Levels of e’ and E/e’ were comparable between male and
female subjects.
In analyses of data from all study subjects, serum FABP4
level was positively correlated with age, BMI, systolic and
diastolic blood pressures, total cholesterol, LDL choles-
terol, triglycerides, insulin, HOMA-R, Cr and hsCRP and
was negatively correlated with eGFR (Table 2). Similar
correlations between the parameters were observed when
male and female subjects were separately analyzed.
Regarding echocardiographic parameters, FABP4 concen-
tration was positively correlated with LA dimension, LA
volume index and mean LV wall thickness (males: r = 0.315,
females: r = 0.401, p < 0.01), though correlation with FABP4
was not significant for LV end-diastolic dimension or
LV mass index. FABP4 level was positively correlated
with E/e’ and negatively correlated with e’ (Figure 1;
males: r = −0.434, females: r = −0.353, p < 0.001), an
index of LV diastolic function, and E/A ratio (Table 2),
whereas LV ejection fraction was not correlated with
FABP4 level. Among echocardiographic parameters, e’
was positively correlated with LV ejection fraction and
E/A ratio and was negatively correlated with LA dimen-
sion, LA volume index, mean LV wall thickness, LV mass
index, E-wave deceleration time and E/e’ (Table 3). Of
extra-cardiac parameters, age, BMI, waist circumference,
systolic and diastolic blood pressures and biochemical
markers, including eGFR, BNP, hsCRP and FABP4, were
found to be significantly correlated with e’ (Table 3).
Multivariate regression analysis was performed to iden-
tify independent determinants of e’ using systolic blood
pressure, the most strongly correlated factor among an-
thropometric and biochemical parameters (r = −0.465,
p < 0.001), in addition to age and gender (Model 1) and
showed that serum FABP4 concentration was independ-
ently correlated with e’ (Table 4). Next, the variables with
a significant and non-confounding correlation in simple
regression analysis were additionally chosen as possible
independent predictors in Model 2 ~ 6: a marker of adi-
posity (BMI, Model 2), glucose and insulin metabolism
(HOMA-R, Model 3), renal function (eGFR, Model 4),
cardiac damage (BNP, Model 5) or cardiac morphology
(LV wall thickness, Model 6). When the each parameter
Table 1 Characteristics of the studied subjects
Whole Male Female
n 190 82 108
Age (years) 63 ± 13 66 ± 13 60 ± 13*
Body mass index (kg/m2) 23.2 ± 3.7 24.4 ± 3.9 22.3 ± 3.4*
Waist circumference (cm) 84 ± 11 88 ± 11 81 ± 10*
Systolic blood pressure (mmHg) 134 ± 21 138 ± 18 130 ± 22*
Diastolic blood pressure (mmHg) 77 ± 11 79 ± 10 75 ± 12†
Biochemical data
Total cholesterol (mg/dl) 202 ± 33 188 ± 29 212 ± 32*
HDL cholesterol (mg/dl) 68 ± 18 59 ± 17 75 ± 16*
LDL cholesterol (mg/dl) 119 ± 29 108 ± 28 127 ± 28*
Triglycerides (mg/dl) 83 (64–112) 93 (70–132) 77 (57–100)*
Glucose (mg/dl) 92 (87–99) 97 (91–103) 90 (85–96)*
HbA1c (%) 5.5 ± 0.5 5.6 ± 0.5 5.4 ± 0.4*
Insulin (μU/ml) 4.5 (3.4-6.9) 4.9 (3.6-7.6) 4.2 (3.2-6.1)*
HOMA-R 1.02 (0.74-1.63) 1.21(0.85-1.92) 0.94 (0.68-1.37)*
Creatinine (mg/dl) 0.74 ± 0.17 0.87 ± 0.16 0.65 ± 0.11*
eGFR (ml/min/1.73 m2) 72 ± 14 71 ± 15 74 ± 14
BNP (pg/ml) 28 (11–31) 14 (9–33) 21 (12–31)
hsCRP (mg/dl) 0.03 (0.02-0.07) 0.04 (0.02-0.08) 0.03 (0.02-0.06)
FABP4 (ng/ml) 12.2 (8.4-16.2) 10.9 (8.1-14.2) 13.3 (9.1-17.0)†
Echocardiographic parameters
Left atrial dimension (mm) 34 ± 6 36 ± 6 33 ± 6*
Left atrial volume index (ml/m2) 27 ± 8 26 ± 8 27 ± 8
Mean LV wall thickness (mm) 8.8 ± 1.2 9.6 ± 0.9 8.2 ± 0.9*
LV end-diastolic dimension (mm) 44 ± 5 45 ± 5 43 ± 4*
LV mass index (g/m2) 93 ± 23 102 ± 22 86 ± 21*
LV ejection fraction (%) 67 ± 5 66 ± 6 67 ± 5†
E/A 0.91 (0.75-1.19) 0.79 (0.68-0.94) 0.98 (0.79-1.31)*
E-wave deceleration time (msec) 214 ± 53 223 ± 59 207 ± 47†
e’ (cm/sec) 10.2 ± 3.1 9.7 ± 3.2 10.6 ± 3.0
E/e’ 7.0 ± 2.3 6.7 ± 2.3 7.3 ± 2.3
Variables are expressed as number, means ± SD or medians (interquartile ranges). BNP, brain natriuretic peptide; eGFR, estimated glomerular filtration rate; hsCRP,
high-sensitivity C-reactive protein; LV, left ventricle. *P < 0.01, †P < 0.05 vs. male.
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remained as an independent predictor of e’ in Model 2 ~ 6
(Table 4), although the independent correlation in Model
2 was cancelled after Holm-Bonferroni sequential cor-
rection. Additional multivariate regression analysis
using all of the used parameters in Model 1 ~ 6, includ-
ing age, gender, systolic blood pressure, BMI, HOMA-R,
eGFR, BNP, mean LV wall thickness and FABP4, showed
that FABP4 level (t = −2.36, p = 0.020) was independently
correlated with e’ after adjustment of other variables
(overall R2 = 0.563).
In low and middle tertiles of BMI, e’ in a group with low
levels of FABP4 (FABP4-Low) was significantly higherthan that in a group with high levels of FABP4 (FABP4-
High) (Figure 2). Furthermore, there was no significant
difference in e’ between the FABP4-Low and FABP4-High
groups in high tertile of BMI, but the FABP4-Low group
in high tertile of BMI had significantly lower e’ than did
that in low tertile of BMI.
Discussion
The salient finding in the present study was that FABP4
was independently and negatively correlated with e’, which
reflects LV relaxation and is known as one of the most
sensitive indexes of LV diastolic function in a healthy
population [14]. LV diastolic dysfunction often precedes
Table 2 Simple regression analysis for log FABP4
Whole (n = 190) Male (n = 82) Female (n = 108)
r p r p r p
Age 0.225 0.002 0.193 0.083 0.314 0.001
Body mass index 0.500 <0.001 0.580 <0.001 0.564 <0.001
Waist circumference 0.518 <0.001 0.642 <0.001 0.518 <0.001
Systolic blood pressure 0.272 <0.001 0.283 0.010 0.329 0.001
Diastolic blood pressure 0.268 <0.001 0.255 0.021 0.329 0.001
Biochemical data
Total cholesterol 0.213 0.003 0.008 0.943 0.282 0.003
LDL cholesterol 0.268 <0.001 0.058 0.606 0.365 <0.001
HDL cholesterol −0.107 0.143 −0.125 0.263 −0.238 0.013
log Triglycerides 0.157 0.031 0.097 0.385 0.282 0.003
log Glucose 0.137 0.060 0.081 0.467 0.277 0.004
HbA1c 0.046 0.532 0.044 0.695 0.107 0.272
log Insulin 0.388 <0.001 0.380 0.001 0.480 <0.001
log HOMA-R 0.386 <0.001 0.384 <0.001 0.489 <0.001
Creatinine 0.192 0.008 0.448 <0.001 0.305 0.001
eGFR −0.350 <0.001 −0.397 <0.001 −0.350 <0.001
log BNP 0.126 0.085 0.076 0.500 0.156 0.108
log hsCRP 0.233 0.001 0.312 0.005 0.218 0.024
Echocardiographic parameters
Left atrial dimension 0.251 0.001 0.354 0.001 0.290 0.002
Left atrial volume index 0.231 0.002 0.226 0.050 0.225 0.020
Mean LV wall thickness 0.195 0.007 0.315 0.004 0.401 <0.001
LV end-diastolic dimension −0.042 0.562 0.069 0.541 −0.082 0.399
LV mass index 0.039 0.596 0.085 0.448 0.105 0.281
LV ejection fraction 0.113 0.121 0.219 0.048 −0.023 0.812
log E/A −0.178 0.016 −0.173 0.131 −0.279 0.004
E-wave deceleration time 0.006 0.934 −0.013 0.906 0.066 0.497
e’ −0.360 <0.001 −0.434 <0.001 −0.353 <0.001
E/e’ 0.353 <0.001 0.361 0.001 0.327 0.001
BNP, brain natriuretic peptide; eGFR, estimated glomerular filtration rate; hsCRP, high-sensitivity C-reactive protein; LV, left ventricle.
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diastolic dysfunction alone potentially induces heart fail-
ure, which is referred to as heart failure with preserved
ejection fraction (HFpEF) [15]. A recent study in which
data from the Framingham cohort study were analyzed
showed that age, diabetes mellitus, BMI, smoking and
atrial fibrillation were predictors of HFpEF [16]. It is
notable that the correlation of FABP4 level with e’ was
independent of age, BMI, HOMA-R and LV wall thickness
(Table 4). These results suggest that serum FABP4 is a
novel marker of LV diastolic dysfunction and potentially a
predictor of HFpEF.
Previous studies using animal models indicated that
FABP4 plays a significant role in several aspects of meta-
bolic syndrome, including insulin resistance, type 2 diabetesand atherosclerosis, through its action at the interface of
metabolic and inflammatory pathways in adipocytes and
macrophages [1,2,4-6]. Epicardial fat has been reported to
directly influence cardiac function because of the absence
of a fibrous fascial layer between fat and the underlying
myocardium [17,18]. FABP4 mRNA expression in epicar-
dial adipose tissue was recently reported to be profoundly
increased compared with its expression in paraaortic
adipose tissue in patients with metabolic syndrome [19].
Furthermore, it has recently been reported that exogenous
FABP4 acutely suppresses shortening amplitude in cardio-
myocytes by attenuating intracellular systolic peak Ca2+
level in a dose-dependent manner [20] and impairs the
insulin-dependent nitric oxide pathway in vascular endo-
thelial cells [21]. Therefore, it is possible that either FABP4
Table 3 Simple regression analysis for LV diastolic function
e’
t p
Age −0.713 < 0.001
Body mass index −0.200 0.006
Waist circumference −0.324 < 0.001
Systolic blood pressure −0.465 < 0.001
Diastolic blood pressure −0.233 0.001
Biochemical data
Total cholesterol −0.071 0.334
LDL cholesterol −0.140 0.054
HDL cholesterol 0.175 0.016
log Triglycerides −0.148 0.042
log Glucose −0.195 0.007
HbA1c −0.210 0.004
log Insulin −0.156 0.032
log HOMA-R −0.187 0.010
Creatinine −0.231 0.001
eGFR 0.376 < 0.001
log BNP −0.394 < 0.001
log hsCRP −0.201 0.006
log FABP4 −0.360 < 0.001
Echocardiographic parameters
Left atrial dimension −0.289 < 0.001
Left atrial volume index −0.233 0.002
Mean LV wall thickness −0.370 < 0.001
LV end-diastolic dimension 0.024 0.739
LV mass index −0.294 < 0.001
LV ejection fraction 0.148 0.043
log E/A 0.644 < 0.001
E-wave deceleration time −0.205 0.005
E/e’ −0.580 < 0.001
BNP, brain natriuretic peptide; eGFR, estimated glomerular filtration rate;
hsCRP, high-sensitivity C-reactive protein; LV, left ventricle.
Figure 1 Association of serum FABP4 level with LV diastolic
dysfunction. Peak myocardial velocity during early diastole (e’), an
index of LV diastolic function, was plotted against log FABP4 for
each subject. There was a significant correlation between the two
parameters (males: r = −0.434, females: r = −0.353, p < 0.001). Open
circles: males (n = 82), closed circles: females (n = 108). Solid
regression line: males, broken regression line: females.
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released from subcutaneous and/or visceral adipose tis-
sue or from macrophages may directly modulate cardiac
function. In the heart, FABP3 known as heart-type FABP
(H-FABP) is abundant and is rapidly released from cells
into the circulation after onset of cardiomyocyte damage.
Serum concentration of FABP3 has been characterized as
an early biochemical marker of acute myocardial infarc-
tion and a sensitive marker of ongoing myocardial damage
in patients with heart failure [22,23]. Impact of circulating
FABP3 is apparently different from that of FABP4.
Inflammation is an important factor in the pathogenesis
and progression of heart failure. It has been shown that in-
creased inflammatory cytokines produced by mononuclear
cells including macrophages and/or damaged myocardium
impaired myocardial function by inducing apoptosis, ne-
crosis and hypertrophic response in cardiomyocytes [24].
In the Framingham Heart Study, increased inflammatory
markers, such as CRP, interleukin-6 and TNFα levels,
were able to identify asymptomatic older subjects in the
community who were at high risk for the future develop-
ment of heart failure [25]. In the present study, FABP4
was positively correlated with hsCRP, being consistent
with the results of several previous studies [10,12]. The
macrophage is a critical site of FABP4 action, and
macrophage-specific FABP4 deficiency leads to reduced
activation of nuclear factor κ B (NF-κB) and c-Jun N-
terminal kinase (JNK), resulting in reduced production
of a cluster of inflammatory cytokines [5]. Conversely,
several inflammatory stimuli have been shown to causesignificantly increased expression of FABP4 in macro-
phages [5]. Local inflammation mediated by FABP4 in
macrophages of the heart may participate in mediating
cardiac dysfunction.
Up-regulation of FABP4 expression and other adipokines
in heart failure has been demonstrated in recent studies
[26-28], indicating complex neurohormonal and metabolic
abnormalities associated with heart failure. Of note, up-
regulation of inflammatory cytokines, catecholamines and
natriuretic peptides in heart failure is known to mediate
increased lipolysis and insulin resistance [29]. It has been
reported that lipolysis is mediated in part through the
interaction of FABP4 with hormone-sensitive lipase in
adipocytes [30]. A recent study also showed that FABP4 is
Table 4 Multivariate regression analysis for LV diastolic function
e’ e’
Model t p Model t p
Model 1 Model 4
Age −10.64 < 0.001 Age −10.27 < 0.001
Gender (Male) −0.31 0.755 Gender (Male) −0.39 0.695
Systolic blood pressure −1.83 0.069 Systolic blood pressure −1.88 0.062
log FABP4 −3.69 < 0.001 eGFR −1.34 0.181
R2 = 0.558 log FABP4 −3.93 < 0.001
R2 = 0.562
Model 2 Model 5
Age −10.64 < 0.001 Age −9.11 < 0.001
Gender (Male) 0.27 0.788 Gender (Male) −0.33 0.744
Systolic blood pressure −1.57 0.118 Systolic blood pressure −1.80 0.073
Body mass index −1.28 0.203 log BNP −0.33 0.742
log FABP4 −2.29 0.023 log FABP4 −3.70 < 0.001
R2 = 0.562 R2 = 0.556
Model 3 Model 6
Age −10.45 < 0.001 Age −10.34 < 0.001
Gender (Male) 0.09 0.925 Gender (Male) 0.17 0.866
Systolic blood pressure −1.74 0.083 Systolic blood pressure −1.62 0.107
log HOMA-R −0.89 0.376 Mean LV wall thickness −0.67 0.503
log FABP4 −3.01 0.003 log FABP4 −3.40 < 0.001
R2 = 0.560 R2 = 0.559
BNP, brain natriuretic peptide; eGFR, estimated glomerular filtration rate; LV, left ventricle.
Figure 2 Comparison of LV diastolic function between subjects
with low and high levels of FABP4 in tertiles of BMI. Peak
myocardial velocity during early diastole (e’), an index of LV diastolic
function, was compared between subjects with low and high levels
of FABP4 divided by median value of FABP4 levels (FABP4-Low and
FABP4-High, respectively) in tertiles of body mass index (BMI). Tertile of
BMI consists of low (<21.4 kg/m2; n = 63), middle (≥21.4 and <24.4 kg/m2;
n = 63), and high (≥24.4 kg/m2; n = 64) groups. *P < 0.05 vs. FABP4-Low.
†P < 0.05 vs. FABP4-Low in BMI (Low).
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way in relation to lipolysis [9]. Although most of the
recruited subjects in the present study were considered to
be healthy, relatively high level of lipolytic stimuli, such as
inflammatory cytokines, catecholamines and natriuretic
peptides, in asymptomatic cardiac dysfunction may increase
serum FABP4 concentration.
Circulating FABP4 level was associated with increased
LV mass in overweight and obese women [31] and in
patients with obstructive sleep apnea syndrome [32].
Recent studies also showed an independent correlation
of elevated serum FABP4 with NT-proBNP in heart failure
patients [33] or deterioration of LV systolic function in
non-obese patients hospitalized for acutely decompensated
heart failure [26] and in patients with coronary artery
disease [34]. In contrast, there was no significant asso-
ciation between FABP4 level and concurrent [32] or
subsequently developed [27] systolic dysfunction in
subjects without obvious cardiac disease. In the present
study using apparently healthy subjects with no medica-
tion, serum FABP4 level was weakly correlated with mean
LV wall thickness but with LV mass index or LV ejec-
tion fraction. These findings suggest only a marginal
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http://www.cardiab.com/content/13/1/126contribution of FABP4 to development of the early phase
of LV hypertrophy and systolic dysfunction.
Similar to our results, a very recent study by Baessler
et al. [35] demonstrated that FABP4 level was inde-
pendently correlated with e’ after adjustment of age,
sex and adiposity in 96 obese subjects and 24 healthy
normal weight control subjects, although the association
of FABP4 levels with LV diastolic dysfunction was mainly
observed in obese subjects with metabolic complications
but not in metabolically healthy obese subjects. However,
LV diastolic dysfunction in the previous study was defined
by combination of several parameters, such as e’ , E/e’ , E/A,
E-wave deceleration time and left atrial dimension. This
definition may affect the results. Of note, we showed that
FABP4 level was an independent predictor of e’ , which is
known as an index of LV relaxation and one of the most
sensitive indicator of LV diastolic function compared with
other indices, especially in a healthy population [14].
A genetic variant at the FABP4 locus associated with
decreased FABP4 expression in adipose tissue has been
reported to reduce the risk of cardiovascular disease in a
population study [36]. We and others previously showed
that serum FABP4 level predicts long-term cardiovascular
events [37-39]. Furthermore, a large-scale prospective study
showed that concentration of FABP4 predicted the risk of
heart failure during a median follow-up of 10.7 years [27].
Accumulating evidence of a causative role of FABP4 in
cardiac dysfunction would prove that FABP4 is a novel
target for prevention of heart failure.
Since FABP4 is a low-molecular-weight protein and
freely filtered at the glomerulus, a decrease in glomerular
function was shown to result in an elevation of FABP4
concentration [37]. In the present study, FABP4 was
negatively correlated with eGFR but remained as an
independent predictor of LV diastolic dysfunction even
after adjusting for renal function. Besides eGFR, multivari-
ate regression analysis demonstrated that the association
of FABP4 level with LV diastolic dysfunction was inde-
pendent of blood pressure, LV wall thickness and BNP, a
well-known predictor of cardiac damage.
The present study has some limitations. Since it has
been reported that several drugs, including statin, angio-
tensin II receptor blocker and peroxisome proliferator-
activated receptor γ agonist, affect FABP4 concentrations
[40-42], we excluded subjects who had been treated with
any drugs in the present study. Therefore, only a small
number of subjects could be enrolled, and the statistical
power was not large. Another limitation of this study is its
cross-sectional design. Prospective longitudinal studies
using larger numbers of subjects with no medication are
necessary for determining whether FABP4 level is indeed
a major determinant of subsequent development of
cardiac dysfunction. In addition, the results of our study
rely on correlation analyses. A direct relationship betweenFABP4 level and progression of LV diastolic dysfunction
remains unclear. This issue warrants further investigation
using an interventional approach.
Conclusions
The present study is the first study to show an independent
association of serum FABP4 level with LV diastolic dysfunc-
tion in a general population. The increase in serum FABP4
concentration might precede development of the early
phase of cardiac dysfunction. Whether FABP4 can serve
as a biomarker for early diagnosis of high-risk individuals
with heart disease and a potential therapeutic target for
cardiac dysfunction warrants further investigation.
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